Analyzing Synaptogenix (NASDAQ:SNPX) and Adhera Therapeutics (OTCMKTS:ATRX)

Synaptogenix (NASDAQ:SNPX) and Adhera Therapeutics (OTCMKTS:ATRX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.

Earnings & Valuation

This table compares Synaptogenix and Adhera Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synaptogenix	N/A	N/A	-$6.04 million	N/A	N/A
Adhera Therapeutics	N/A	N/A	-$2.11 million	N/A	N/A

Analyst Ratings

This is a summary of recent ratings for Synaptogenix and Adhera Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synaptogenix	0	0	1	0	3.00
Adhera Therapeutics	0	0	0	0	0.00

Synaptogenix currently has a consensus price target of $14.00, indicating a potential upside of 345.86%. Given Synaptogenix’s stronger consensus rating and higher possible upside, equities analysts clearly believe Synaptogenix is more favorable than Adhera Therapeutics.

Profitability

This table compares Synaptogenix and Adhera Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Synaptogenix	N/A	-42.14%	-29.42%
Adhera Therapeutics	N/A	N/A	N/A

Insider and Institutional Ownership

10.3% of Synaptogenix shares are held by institutional investors. 2.7% of Synaptogenix shares are held by insiders. Comparatively, 28.2% of Adhera Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Risk & Volatility

Synaptogenix has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500. Comparatively, Adhera Therapeutics has a beta of 3.34, suggesting that its share price is 234% more volatile than the S&P 500.

Summary

Adhera Therapeutics beats Synaptogenix on 5 of the 9 factors compared between the two stocks.

About Synaptogenix

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. The company was incorporated in 2012 and is headquartered in New York, New York.

About Adhera Therapeutics

Adhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of Parkinson's disease; and MLR -1023 to treat Type 1 diabetes. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana.